Outcome of Board meeting_Completion of tenure of Satutory Auditors

Biocon's Board meeting on May 7, 2026 approved multiple key items: (1) Audited financial results for Q4 and FY ended March 2026; (2) Recommended final dividend of Rs. 0.50 per share (10%) for FY2026 with record date July 3, 2026; (3) Appointed S.R. Batliboi & Associates LLP as new statutory auditors for 5 years, replacing B S R & Co. LLP whose term ends at the 48th AGM; (4) Designated Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer - Emerging Markets as Senior Management Personnel; (5) Approved re-appointment of Ms. Rekha Mehrotra Menon as Independent Director and appointment of 5 new Independent Directors including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Chandavarkar, and Ms. Nivruti Rai, plus Mr. Thomas Jason Roberts as Non-Executive Non-Independent Director (effective August 1, 2026); (6) Approved acquisition of remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) via preferential share issuance of 87,92,317 equity shares at Rs. 376.16 per share (worth Rs. 330.73 Crores), converting OCDs and CCDs of BBL into equity, taking BBL ownership to ~99.99%; (7) Approved Biocon Unity Long-Term Incentive Plan 2026.